Breaking News Instant updates and real-time market news.

NVS

Novartis

$85.88

1.1 (1.30%)

, JNJ

Johnson & Johnson

$127.80

1.99 (1.58%)

04:55
01/06/19
01/06
04:55
01/06/19
04:55

Sachs Associates to hold a forum

2nd Annual Neuroscience Innovation Forum will be held in San Francisco on January 6.

NVS

Novartis

$85.88

1.1 (1.30%)

JNJ

Johnson & Johnson

$127.80

1.99 (1.58%)

LLY

Eli Lilly

$114.65

3.36 (3.02%)

BIIB

Biogen

$318.19

11.62 (3.79%)

AGN

Allergan

$142.64

6.59 (4.84%)

NTRP

Neurotrope

$3.85

0.04 (1.05%)

CCORF

Canaccord Financial

$0.00

(0.00%)

BCLI

BrainStorm

$3.37

-0.03 (-0.88%)

TNXP

Tonix Pharmaceuticals

$2.15

0.07 (3.37%)

CVSI

CV Sciences

$0.00

(0.00%)

CGC

Canopy Growth

$28.21

0.09 (0.32%)

ABBV

AbbVie

$89.04

2.89 (3.35%)

SF

Stifel Financial

$42.09

2.06 (5.15%)

RLMD

Relmada Therapeutics

$0.00

(0.00%)

  • 06

    Jan

  • 06

    Jan

  • 06

    Jan

  • 07

    Jan

  • 07

    Jan

  • 07

    Jan

  • 14

    Jan

  • 14

    Jan

  • 22

    Jan

  • 25

    Jan

  • 27

    Jan

  • 28

    Jan

  • 29

    Jan

  • 29

    Jan

  • 18

    Feb

  • 18

    May

NVS Novartis
$85.88

1.1 (1.30%)

01/02/19
JPMS
01/02/19
DOWNGRADE
JPMS
Underweight
Novartis downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Richard Vosser downgraded Novartis to Underweight with a price target of CHF 89. The analyst has concerns over the company's pipeline and believes the shares are close to fair value.
12/11/18
JEFF
12/11/18
INITIATION
Target $105
JEFF
Buy
Novartis assumed with a Buy at Jefferies
Jefferies analyst Peter Welford assumed coverage of GNovartis with a Buy rating and $105 price target. The analyst is positive on the European large-cap Pharma space "as it enters a period of sustained earnings momentum."
12/20/18
WELS
12/20/18
NO CHANGE
WELS
Drug industry facing 'brave new world' with drug price scrutiny, says Wells
After Reuters reported that nearly 30 drugmakers are planning to raise the prices of their medicines in the U.S. starting in January, including Novartis (NVS), Bayer (BAYRY), GlaxoSmithKline (GSK), Amgen (AMGN), AstraZeneca (AZN), Biogen (BIIB) and Allergan (AGN), Wells Fargo analyst David Maris told investors in a research note that he has repeatedly highlighted how the practice of drug price increases is a risk for the industry, and believes the latest actions by these manufacturers will be "front and center" for the Trump administration heading towards an election year. He also expects to see increased political and legislative pressure on drug prices as Democrats take over the House in January, and continues to believe that the drug industry is facing a "brave new world" with greater scrutiny of drug prices, lower price increases vs. historical levels, and as a result potentially lower profit margins.
12/18/18
COWN
12/18/18
NO CHANGE
COWN
Outperform
Cowen sees Sandoz deal as reinforcing Tilray's competitive positioning
Tilray's (TLRY) expanded global partnership with Novartis (NVS) division Sandoz can not only help expand its reach with pharmacists, physicians and distributors, it can also help Tilray capture early share in new medical cannabis markets as they come online, Cowen analyst Vivien Azer tells investors in a research note. Further, the analyst believes the partnership also helps legitimize cannabis in international markets, which could help influence countries considering medical cannabis legalization. Azer estimates international will represent 15% of Tilray's revenue in fiscal 2020 and 22% in fiscal 2021. Not only does the deal allow Tilray to expand geographic reach, but also to grow at scale, says Azer. And most notably, the Sandoz deal reinforces Tilray's competitive positioning, adds the analyst, who keeps an Outperform rating on the shares with a $150 price target. The stock in morning trading is up 9%, or $5.98, to $71.87.
JNJ Johnson & Johnson
$127.80

1.99 (1.58%)

12/20/18
WELS
12/20/18
NO CHANGE
WELS
Outperform
No change in talc litigation risk for Johnson & Johnson, says Wells Fargo
Wells Fargo analyst Larry Biegelsen notes that the NY Times reported that Johnson & Johnson has lost its bid to overturn the $4.7B in a talc trial in St. Louis in July 2018. After checking with the company, the analyst is "able to confirm" that the decision relates to the trial judge denying Johnson & Johnson's post trial motion to set aside the $4.7B verdict. Biegelsen understands that the company had to file this motion in order to file its actual appeal of the decision with the appellate court. As such, he believes the judge's decision should not materially affect the overall talc situation for Johnson & Johnson. Wells Fargo has an Outperform rating on the shares.
01/02/19
SBSH
01/02/19
NO CHANGE
SBSH
Citi makes four rating changes in Medical Devices, 'warning up' to J&J
Citi analyst Amit Hazan issued his 2019 preview for Medical Devices, which included four rating changes. The analyst upgraded both Zimmer Biomet (ZBH) and Baxter International (BAX) to Buy from Neutral, downgraded Medtronic (MDT) to Neutral from Buy and downgraded Abbott Laboratories (ABT) to Sell from Neutral. He also kept Buy ratings on Intuitive Surgical (ISRG) and Boston Scientific (BSX), but adds he's "relatively more cautious." Further, Hazan kept a Sell rating on Edwards Lifesciences (EW) and says he's "warming up" to Neutral-rated Johnson & Johnson (JNJ). The analyst expects "fairly stable" fundamentals for the group in 2019, with "modest slowdowns" in organic sales and earnings growth.
01/04/19
CANT
01/04/19
NO CHANGE
Target $100
CANT
Overweight
Cantor Fitzgerald analysis suggests others could bid for Celgene
Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating on Celgene (CELG) with a $100 price target after the company reached an agreement to be acquired by Bristol-Myers Squibb (BMY). Bristol "likely got a good deal, although Celgene has intellectual property and pipeline uncertainties that are key moving pieces," Young tells investors in a research note. Her estimated net present value for Celgene is $80B, assuming some cost synergies, versus the $74B equity valuation in the Bristol deal, excluding the contingent value rights. Young's analysis indicates that companies like Amgen (AMGN) and Johnson & Johnson (JNJ) "could potentially achieve greater commercial synergies." However, the analyst thinks Celgene shareholders "may be satisfied with the current deal after quite a roller-coaster over the past 18 months."
01/04/19
BTIG
01/04/19
NO CHANGE
Target $17
BTIG
Buy
Veracyte price target raised to $17 from $15 at BTIG
BTIG analyst Sung Ji Nam raised his price target on Veracyte (VCYT) to $17 and kept the Buy rating on the shares after its announced long term partnership with Johnson & Johnson (JNJ) yesterday. The analyst says the collaboration aims to accelerate the development of the first nasal swab test for early lung cancer detection and involve the two companies sharing existing data and samples from clinical studies. Sung Ji Nam states that the deal should lead to acceleration of next -gen Percepta launch, adding that the nasal swab test development could quadruple the company's total addressable market value in the U.S. alone.
LLY Eli Lilly
$114.65

3.36 (3.02%)

12/24/18
BMOC
12/24/18
NO CHANGE
Target $132
BMOC
Outperform
Eli Lilly price target raised to $132 from $124 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Eli Lilly to $132 from $124 and kept his Outperform rating, saying that unlike its peers, the company offers "multiple growth drivers and several pipeline assets that could provide meaningful upside." The analyst anticipates Eli Lilly's annualized revenue and earnings growth of 5% and 16% with "significant upside potential" coming from Tanezumab and Alzheimer's program. Araeil further believes that the company's growth, strong R&D and commercial execution prospects "support its premium valuation."
12/27/18
ARGS
12/27/18
NO CHANGE
Target $135
ARGS
Buy
Argus sees volume growth, expanded indications as 2019 catalysts for Eli Lilly
Argus analyst David Toung kept his Buy rating and $135 price target on Eli Lilly, saying its 2019 catalysts for upside include anticipated volume growth and expanded indications for existing drugs, along with "potential regulatory approvals". The analyst notes that while the company's mature products are seeing slower sales and face patent expiration and the loss of exclusivity, he also expects Eli Lilly to generate earnings growth from margin expansion. Toung is also confident in 2019 contribution of Eli Lilly's recently launched Olumiant for rheumatoid arthritis, Verzenio for the second-line treatment of breast cancer, and Taltz for active psoriatic arthritis.
12/31/18
CANT
12/31/18
NO CHANGE
Target $53
CANT
Overweight
Doctors impressed by tanezumab data, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen says that investors she's spoken with are expecting the data for Pfizer (PFE) and Eli Lilly's (LLY) tanezumab in the first half of 2019 to be similar to or worse than what was seen in the first Phase 3 data set reported on October 23. However, physicians are impressed by the data and do not believe the rapidly progressive osteoarthritis imbalance would impact their desire to prescribe tanezumab if it is approved, Chen tells investors in a research note. The analyst believes the safety for tanezumab will be better than expected and that the drug could replace opioids for the treatment of pain. If that is right, peak sales potential of tanezumab could be billions of dollars, and drive upside to modest expectations for the drug, says the analyst. She keeps an Overweight rating on Pfizer with a $53 price target.
12/20/18
LEHM
12/20/18
NO CHANGE
Target $120
LEHM
Overweight
Eli Lilly update 'bolsters bullish outlook,' says Barclays
Barclays analyst Geoff Meacham believes Eli Lilly's update yesterday bolstered its bullish outlook. The company's new product growth underscores an attractive investment case, Meacham tells investors in a research note. While the initial 2019 guidance was "solidly ahead of expectations," what is more impressive is the underlying quality, with new products set to drive 45% of 2019's growth outlook, says the analyst. He keeps an Overweight rating on Eli Lilly with a $120 price target.
BIIB Biogen
$318.19

11.62 (3.79%)

01/03/19
PIPR
01/03/19
NO CHANGE
PIPR
Piper sees Alexion, Biogen as potential targets after Celgene buyout
Piper Jaffray analyst Christopher Raymond remains "bullish on biotech" in the wake the announced acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) for $74B in cash and stock, representing a 54% premium from yesterday's close. In a research note titled "Bristol for CELG - In Retrospect, it Makes Perfect Sense," Raymond says the market is likely to ask "who's next?" Among large-caps, Alexion Pharmaceuticals (ALXN) and Biogen (BIIB) would seem to make sense as potential targets, as well as BioMarin (BMRN), Raymond writes. And while any smid cap could likely be seen as a take-out candidate, Aimmune Therapeutics (AIMT), Deciphera Pharmaceuticals (DCPH) and Rigel Pharmaceuticals (RIGL) "in particular could make sense to any strategic buyer," adds the analyst.
12/21/18
12/21/18
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. NXP Semiconductors (NXPI) initiated with an Overweight at Piper Jaffray. 2. Biogen (BIIB) initiated with a Buy at BTIG. 3. Allena Pharmaceuticals (ALNA) assumed with a Buy at B. Riley FBR. 4. WWE (WWE) initiated with a Hold at Loop Capital. 5. Applied Materials (AMAT) initiated with a Buy at Needham. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/01/19
PIPR
01/01/19
NO CHANGE
Target $400
PIPR
Overweight
Biogen raised prices on MS drugs meaningfully today, says Piper Jaffray
According to Wolters Kluwer Health, Biogen took "meaningful" price increases across its multiple sclerosis franchise effective January 1, 2019, Piper Jaffray analyst Christopher Raymond tells investors in a research note titled "Starts The New Year Off With Spate of Price Increases." The timing and magnitudes of the increases are consistent with Biogen's established pattern, adds the analyst. Raymond, however, finds the company's increases this year notable, "especially in an environment of increasing drug pricing scrutiny on both the political and policy front." Biogen took a price increase of 6% for Tecfidera, 3.5% for Tysabri and 2% each for Avonex and Plegridy, he explains. Given President Trump's Drug Pricing Blueprint and his willingness to call out individual companies for price increases, the analyst thinks some investors will be surprised by Biogen's 2019 increases. He remains a buyer of Biogen shares with an Overweight rating and $400 price target. The stock closed Monday up $7.40 to $300.92.
12/21/18
BTIG
12/21/18
INITIATION
Target $362
BTIG
Buy
BTIG starts Biogen with Buy rating, $362 price target
BTIG analyst Thomas Shrader last night initiated coverage of Biogen with a Buy rating and $362 price target. The analyst sees the company as well positioned with a "history of investing in imaging approaches for R&D, a hard-nosed business culture, a focus on neuroscience, and a cash-cow stable" of multiple sclerosis drugs. Further, Shrader expects "excitement to build over the aducanumab" story as we near the first Phase 3 readouts.
AGN Allergan
$142.64

6.59 (4.84%)

12/19/18
RAJA
12/19/18
NO CHANGE
Target $198
RAJA
Outperform
Selloff in Allergan shares 'overdone,' says Raymond James
Raymond James analyst Elliot Wilbur notes that the French regulatory authority ANSM has issued a communique indicating that Allergan's CE Mark for the company's line of textured breast implants sold in various European countries will not be renewed based on input from GMED, the official French medical device certification body. Allergan can no longer sell textured breast implants in France and other affected European markets, and the company has ceased sales and commenced a recall of all existing supply, he adds. The analyst acknowledges that this is a "surprise but certainly not an unknown." Further, Wilbur believes reaction is "overdone" and shares should be "aggressively accumulated" on the move. He reiterates an Outperform rating and $198 price target on the stock.
12/19/18
LEER
12/19/18
NO CHANGE
LEER
Outperform
Allergan selloff today a buying opportunity, says Leerink
Leerink analyst Marc Goodman views today's 7% selloff in shares of Allergan based on the breast implant news as a buying opportunity. While the suspension of sales is an incremental negative and likely to bring down consensus numbers, 2019 should bring increasingly visibility for Botox durability and the company's the pipeline, Goodman tells investors in a research note. He keeps an Outperform rating on Allergan, which is down $11.01 to $135.82 in afternoon trading.
01/02/19
01/02/19
DOWNGRADE
Target $39

Underweight
Morgan Stanley sees more underperformance for Hologic, downgrades to Underweight
As previously reported, Morgan Stanley analyst David Lewis downgraded Hologic (HOLX) to Underweight from Equal Weight, stating that his checks with about 40 medspas highlighted market saturation of body sculpting devices. This, coupled with Allergan's (AGN) recent announcement of discounting CoolSculpting to drive its installed base, suggests Hologic's acquisition of Cynosure may not be as accretive as expected, Lewis tells investors. Additionally, in the company's Surgical segment, he expects NovaSure will continue to lose share as procedures shift to the office where NovaSure is less popular given periprocedural pain. Given both of these views, Lewis views Hologic as less attractive relative to peers and cut his price target on the stock to $39 from $44.
NTRP Neurotrope
$3.85

0.04 (1.05%)

05/16/18
MAXM
05/16/18
INITIATION
Target $16
MAXM
Buy
Neurotrope initiated with a Buy at Maxim
Maxim started Neurotrope with a Buy rating and $16 price target.
03/08/18
ROTH
03/08/18
INITIATION
Target $15
ROTH
Buy
Neurotrope initiated with a Buy at Roth Capital
Roth Capital analyst Robert LeBoyer started Neurotrope with a Buy rating and $15 price target.
CCORF Canaccord Financial
$0.00

(0.00%)

BCLI BrainStorm
$3.37

-0.03 (-0.88%)

05/15/18
HCWC
05/15/18
INITIATION
Target $11
HCWC
Buy
BrainStorm initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert initiated BrainStorm with a Buy and $11 price target saying it is developing a first of its kind cell therapy, called NurOwn, for the treatment of Amyotrophic Lateral Sclerosis, or ALS. Kolbert said NurOwn has an established clean safety profile and convenient dosing, but also has the potential to be disease modifying, slowing down disease progression. This, combined with orphan status for a 30K U.S. and 55K EU patient market, establish real value in the company.
06/26/18
HCWC
06/26/18
NO CHANGE
Target $11
HCWC
Buy
BrainStorm 'distressed' valuation an opportunity, says H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert noted that Brainstorm announced that it will not make NurOwn available under the newly enacted "Right to Try" Act. Management deemed this impractical since the unapproved ALS treatment would only be available to those who can afford it, which would be unethical. The focus must be on completing the clinical program so the therapy can be made available to all with reimbursement, said Kolbert, who thinks Brainstorm's current valuation is "distressed" at a market capitalization below $100M despite its lead program being in a pivotal trial. He maintains a Buy rating and $11 price target on Brainstorm shares.
10/29/18
HCWC
10/29/18
NO CHANGE
Target $11
HCWC
Buy
BrainStorm's 'distressed valuation' presents opportunity, says H.C. Wainwright
After BrainStorm Cell Therapeutics reported that it spent "just" $3.2M in the third quarter and management reiterated that they continue to anticipate the ALS pivotal trial enrollment is on track to complete by mid-2019, H.C. Wainwright analyst Jason Kolbert said he view's Brainstorm's current valuation as "distressed" given NurOwn's clean safety profile and the fact that it is in a pivotal trial. Applying a 70% probability of success, he maintains a Buy rating and $11 price target on BrainStorm shares.
TNXP Tonix Pharmaceuticals
$2.15

0.07 (3.37%)

07/27/18
ROTH
07/27/18
DOWNGRADE
ROTH
Neutral
Tonix Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
07/27/18
RILY
07/27/18
DOWNGRADE
Target $1.25
RILY
Neutral
Tonix Pharmaceuticals downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Tonix Pharmaceuticals to Neutral and cut his price target for the shares to $1.25 from $8. The downgrade follows Tonix's decision to stop the Phase III Honor study of Tonmya in military-related post-traumatic stress disorder. The stock in morning trading is down 65%, or $2.57, to $1.38.
07/27/18
ROTH
07/27/18
DOWNGRADE
Target $1
ROTH
Neutral
Tonix Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Scott Henry downgraded Tonix Pharmaceuticals to Neutral from Buy and lowered his price target to $1 from $6 following "disappointing" results from its interim Phase 3 analysis of Tonmya for the treatment of posttraumatic stress disorder. In a research note to investors, Henry notes that the trial was halted as the primary endpoint did not have adequate separation from placebo on the primary endpoint at week 12. While Henry notes that the data at week 4 of the trial did show separation from placebo for CAPS-5 and Clinical Global Impression - Improvement, he contends that PTSD is a "challenging" therapeutic category, and that although the FDA could allow for a shorter duration endpoint, "we view that as the exception as opposed to the rule." Henry does not expect a rebound in shares pending clarity from the FDA on the future pathway utilizing a shorter endpoint, and says shares are "no longer investable for most" due to an uncertain clinical risk profile and financial risk.
06/06/18
RILY
06/06/18
INITIATION
Target $8
RILY
Buy
Tonix Pharmaceuticals initiated with a Buy at B. Riley FBR
B. Riley FBR analyst David Buck started Tonix Pharmaceuticals with a Buy rating and $8 price target. The analyst sees an attractive risk/reward ahead of a potential near-term catalyst for the company's treatment of post-traumatic stress disorder.
CVSI CV Sciences
$0.00

(0.00%)

09/20/18
STFL
09/20/18
NO CHANGE
STFL
Top 22 Canadian cannabis stocks up 127% since Constellation pact, says Stifel
Yesterday's significant outperformance for Canadian cannabis stocks, led by Tilray (TLRY), at one point pushed the total market capitalization for Canadian Licensed Producers above $C80B, before they closed with a combined market cap of C$73B, calculates Stifel analyst Christopher Growe. Since August 15, when Constellation Brands (STZ) announced a pact to invest C$5B into Canopy Growth (CGC), the top 22 Canadian cannabis stocks are up 127% in stock price, noted Growe. A $C73B market cap in relation to what he estimates to be an addressable Canadian market of C$10B is "difficult to fathom," so valuations require global opportunities to be realized, added Growe, who said he questions the pace of development and degree of advantage for these companies. Companies in the cannabis space that can be traded in the U.S. include Aurora Cannabis (ACBFF), CV Sciences (CVSI), Canopy Growth, Cronos Group (CRON) and Tilray.
10/17/18
MSCO
10/17/18
NO CHANGE
MSCO
Morgan Stanley says pot legalization could pose risk to Canadian auto insurers
Morgan Stanley analyst Kai Pan noted that academic studies do not agree on the potential impact on car accidents from legalized recreational use of marijuana, but he still believes Canada's legalization could pose a risk to Canadian auto insurers. IFC, the largest auto insurer in Canada, is not immune to this challenge but given its long-term outperformance versus peers and strong claims management, Pan thinks the company should be better positioned in addressing this challenge, he tells investors. Publicly traded companies in the cannabis space include Aurora Cannabis (ACBFF), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC) and Tilray (TLRY).
11/07/18
ADAM
11/07/18
NO CHANGE
ADAM
Midterms broadly positive for U.S. cannabis industry, says Canaccord
Canaccord analyst Bobby Burleson says that as expected, yesterday's midterms delivered several wins for the U.S. cannabis industry, including the passage of three state ballot measures on legalization, key gubernatorial victories by pro-cannabis candidates, and the retaking of the House by Democrats. The analyst views these results as broadly positive for the U.S. cannabis industry. Publicly traded companies in the space include Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC) and Tilray (TLRY).
CGC Canopy Growth
$28.21

0.09 (0.32%)

01/04/19
WELS
01/04/19
NO CHANGE
Target $260
WELS
Outperform
Constellation 'one of the most attractive stocks' in Staples, says Wells Fargo
Wells Fargo analyst Bonnie Herzog reiterated an Outperform rating and $260 price target on Constellation Brands (STZ), telling investors in a research note that she believes Constellation is one of the most attractive stocks in Staples, given scarcity of growth across the group and the pullback, which she says is "unjustified." While she expects Constellation to lower FY19 EPS guidance to reflect 25c-30c of interest expense from the increased stake in Canopy Growth (CGC), Herzog believes Q3 results may surprise to the upside based on strong performance in Nielsen scanner data through December and potential beer margin upside from lower marketing investments. She sees Q3 results as a potential positive catalyst and encourages long-term investors to accumulate positions in the stock.
01/03/19
BNCH
01/03/19
NO CHANGE
BNCH
Activision, Canopy Growth among Best Ideas for first half of 2019 at Benchmark
Benchmark analysts selected their Best Ideas for the first half of 2019, naming 16 stocks, including: Activision Blizzard (ATVI), BioTelemetry (BEAT), Biofrontera (BFRA), Ctrip (CTRP), Huazhu Group (HTHT), II-VI (IIVI), Intevac (IVAC), LHC Group (LHCG), Meredith (MDP), Marvell (MRVL), NeoGenomics (NEO), Pegasystems (PEGA), Silicon Labs (SLAB), Varonis (VRNS), Canopy Growth (CGC) and Waitr Holdings (WTRH).
12/10/18
JEFF
12/10/18
NO CHANGE
Target $289
JEFF
Buy
Constellation still top large cap growth idea after Canopy meeting at Jefferies
Jefferies analyst Kevin Grundy says Constellation Brands (STZ) remains his top large cap growth idea following his meeting with cannabis Canopy Growth (CGC), which is 40% owned by Constellation. The analyst came away impressed by Canopy's leadership, encouraged by its ability to capitalize on the "massive" global cannabis opportunity, and reassured by its confidence to deliver the "scrutinized" C$1B in revenue in 2020. He views Constellation's risk/reward as favorable and keeps a Buy rating on the shares with a $289 price target.
12/10/18
COWN
12/10/18
NO CHANGE
Target $260
COWN
Outperform
Constellation Brands a 'shooting star flying under the radar,' says Cowen
Cowen analyst Vivien Azer told investors in a research note that Constellation Brands (STZ) remains her overall Top Pick across all of the companies under her coverage going into 2019, contending that best in class revenue growth within U.S. beer, coupled with strong profitability has afforded Constellation the opportunity to leverage this strong operating performance and position it to win over the long term with its notable $4B investment in market leading Canopy Growth (CGC). Azer maintains an Outperform rating and $260 price target on Constellation shares.
ABBV AbbVie
$89.04

2.89 (3.35%)

01/03/19
BOFA
01/03/19
DOWNGRADE
Target $95
BOFA
Neutral
AbbVie downgraded to Neutral from Buy at BofA/Merrill
As noted earlier, BofA/Merrill analyst Jason Gerberry downgraded AbbVie to Neutral from Buy and lowered his price target to $95 from $98 as part of his broader research note on the Phamaceuticals sector partially titled "Preference for value, defensive + pipeline optionality". The analyst sees "limited upside to shares" relative to his price objective and also cites a more "unfavorable macro backdrop for companies with high single product concentration risk". Gerber believes that AbbVie would have to "meaningfully beat consensus forecasts on key new product launches" to reduce investor concerns over the loss of exclusivity for Humira and Imbruvica.
01/03/19
01/03/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Hold from Buy at Jefferies and Loop Capital, as well as to Neutral from Outperform at Macquarie. 2. Genesee & Wyoming (GWR) downgraded to Equal Weight from Overweight at Stephens with analyst Justin Long citing his view that a re-expansion in valuation multiples could be more challenging in the near-term given North American volume headwinds in the short line network, unknowns around the PSR impact and more concerning international macro data points. 3. Lumber Liquidators (LL) downgraded to Hold from Buy at Loop Capital with analyst Laura Champine saying she reduced her margin forecast to reflect a promotional environment. 4. American Electric (AEP) downgraded to Neutral from Buy at Mizuho with analyst Paul Fremont citing valuation. 5. AbbVie (ABBV) downgraded to Neutral from Buy at BofA/Merrill with analyst Jason Gerberry saying he sees "limited upside to shares" relative to his price objective and also cites a more "unfavorable macro backdrop for companies with high single product concentration risk." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/26/18
STPT
12/26/18
INITIATION
STPT
Buy
AbbVie initiated with a Buy at Standpoint Research
Standpoint Research analyst Ronnie Moas initiated AbbVie with a Buy rating.
01/03/19
BOFA
01/03/19
DOWNGRADE
BOFA
Neutral
AbbVie downgraded to Neutral from Buy at BofA/Merrill
SF Stifel Financial
$42.09

2.06 (5.15%)

12/19/18
WELS
12/19/18
DOWNGRADE
WELS
Market Perform
Stifel Financial downgraded to Market Perform from Outperform at Wells Fargo
11/27/18
GSCO
11/27/18
INITIATION
Target $56
GSCO
Neutral
Stifel Financial initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Alexander Blostein started Stifel Financial with a Neutral rating and $56 price target. Blostein initiated the smid-cap Brokers with an Attractive coverage view and names LPL Financial (LPLA) his top pick. The analyst sees "good upside" for Stifel amid "robust" 2019 net investment income growth and "significant" share repurchases. However, risks within its Capital Markets business and limited earnings upside relative to consensus keep him sidelined.
11/27/18
11/27/18
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. CVS Health (CVS) initiated with an Overweight at Cantor Fitzgerald. 2. EVO Payments (EVOP) initiated with a Buy at BTIG. 3. Coherent (COHR) initiated with a Buy at Vertical Group. 4. LPL Financial (LPLA) was initiated with a Conviction Buy at Goldman Sachs while CalAmp (CAMP), Stifel Financial (SF), and Raymond James (RJF) initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/19/18
WELS
12/19/18
DOWNGRADE
Target $44
WELS
Market Perform
Wells Fargo sees 'challenges ahead' for Stifel, downgrades to Market Perform
Wells Fargo analyst Christopher Harris downgraded Stifel Financial to Market Perform and lowered his price target for the shares to $44 from $49. The analyst sees "challenges ahead" for the company. The current quarter is likely to represent the peak for profit margins this cycle, and revenue growth will be "much harder to achieve" in 2019, Harris tells investors in a research note. The analyst reduced his estimates for Stifel to reflect lower revenue expectations and higher credit costs.
RLMD Relmada Therapeutics
$0.00

(0.00%)

TODAY'S FREE FLY STORIES

EFC

Ellington Financial

$18.79

0.01 (0.05%)

20:29
11/18/19
11/18
20:29
11/18/19
20:29
Syndicate
Ellington Financial 4.2M share Spot Secondary priced at $18.20 »

The stock priced below…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

HD

Home Depot

$238.98

1.64 (0.69%)

, MDT

Medtronic

$111.25

-0.86 (-0.77%)

20:25
11/18/19
11/18
20:25
11/18/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

HD

Home Depot

$238.98

1.64 (0.69%)

MDT

Medtronic

$111.25

-0.86 (-0.77%)

TJX

TJX

$59.54

-0.25 (-0.42%)

TDG

TransDigm

$568.32

9.81 (1.76%)

ARMK

Aramark

$43.90

0.25 (0.57%)

KSS

Kohl's

$58.39

-0.71 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 05

    Dec

  • 11

    Dec

ACY

AeroCentury

$3.31

-0.66 (-16.62%)

20:01
11/18/19
11/18
20:01
11/18/19
20:01
Hot Stocks
AeroCentury sells one Bombardier CRJ900 to Aeronautical Support International »

AeroCentury announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$6.02

-0.14 (-2.27%)

19:29
11/18/19
11/18
19:29
11/18/19
19:29
Hot Stocks
Myovant Sciences up over 11% after announcing Phase 3 Study conference call »

Shares of Myovant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$29.95

-0.04 (-0.13%)

18:47
11/18/19
11/18
18:47
11/18/19
18:47
Hot Stocks
Invitation Homes CEO sells 70K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$369.50

-2.05 (-0.55%)

, LUV

Southwest

$57.77

-0.03 (-0.05%)

18:44
11/18/19
11/18
18:44
11/18/19
18:44
Periodicals
Boeing to provide Southwest board with 737 MAX update this week, Reuters says »

Boeing (BA) this week…

BA

Boeing

$369.50

-2.05 (-0.55%)

LUV

Southwest

$57.77

-0.03 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 23

    Jan

GBDC

Golub Capital

$17.79

0.045 (0.25%)

18:42
11/18/19
11/18
18:42
11/18/19
18:42
Upgrade
Golub Capital rating change at Keefe Bruyette »

Golub Capital upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

GM

General Motors

$36.62

-0.25 (-0.68%)

, TM

Toyota

$143.53

-0.76 (-0.53%)

18:42
11/18/19
11/18
18:42
11/18/19
18:42
Periodicals
CA to halt purchase of GM, Toyota, Fiat Chrysler vehicles, Reuters reports »

The state of California…

GM

General Motors

$36.62

-0.25 (-0.68%)

TM

Toyota

$143.53

-0.76 (-0.53%)

FCAU

Fiat Chrysler

$15.63

-0.39 (-2.43%)

NSANY

Nissan

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

CRMT

America's Car-Mart

$90.88

3.22 (3.67%)

, WUBA

58.com

$50.26

-1.35 (-2.62%)

18:38
11/18/19
11/18
18:38
11/18/19
18:38
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

CRMT

America's Car-Mart

$90.88

3.22 (3.67%)

WUBA

58.com

$50.26

-1.35 (-2.62%)

BILI

Bilibili

$16.39

-0.32 (-1.92%)

SAEX

SAExploration

$1.51

-0.05 (-3.21%)

CLVS

Clovis

$7.05

0.68 (10.68%)

NOW

ServiceNow

$266.56

6.65 (2.56%)

OKTA

Okta

$121.21

3.76 (3.20%)

SPLK

Splunk

$122.64

3.49 (2.93%)

WWD

Woodward

$113.64

-1.15 (-1.00%)

KRNT

Kornit Digital

$33.07

-1.13 (-3.30%)

ASH

Ashland

$78.65

0.03 (0.04%)

VNET

21Vianet

$8.28

0.23 (2.86%)

DHT

DHT Holdings

$7.52

-0.2 (-2.59%)

KRTX

Karuna Therapeutics

$94.70

77.44 (448.67%)

EGHT

8x8, Inc.

$20.78

0.13 (0.63%)

I

Intelsat

$7.98

-5.42 (-40.45%)

PFGC

Performance Food Group

$46.09

-0.08 (-0.17%)

EFC

Ellington Financial

$18.79

0.01 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 21

    Nov

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 12

    Dec

  • 16

    Dec

  • 19

    Nov

  • 19

    Nov

  • 21

    Nov

  • 21

    Nov

LEVI

Levi Strauss

$17.06

-0.115 (-0.67%)

18:31
11/18/19
11/18
18:31
11/18/19
18:31
Hot Stocks
Levi Strauss CEO: I believe in the importance of innovation »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$45.17

0.07 (0.16%)

18:17
11/18/19
11/18
18:17
11/18/19
18:17
Periodicals
Cisco sues former employees over claims of trade secret theft, Bloomberg says »

Cisco is suing two…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 12

    Feb

ABBV

AbbVie

$88.71

0.07 (0.08%)

18:09
11/18/19
11/18
18:09
11/18/19
18:09
Hot Stocks
AbbVie treatment of myelofibrosis granted FDA orphan status »

AbbVie's navitoclax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

PRQR

ProQR Therapeutics

$6.27

-0.64 (-9.26%)

18:06
11/18/19
11/18
18:06
11/18/19
18:06
Hot Stocks
ProQR Therapeutics treatment of retinal dystrophy in P23H granted orphan status »

ProQR Therapeutics'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BILI

Bilibili

$16.39

-0.32 (-1.92%)

18:04
11/18/19
11/18
18:04
11/18/19
18:04
Earnings
Bilibili sees Q4 revenue RMB1.93B-RMB1.98B »

Q4 revenue consensus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

WUBA

58.com

$50.26

-1.35 (-2.62%)

18:03
11/18/19
11/18
18:03
11/18/19
18:03
Earnings
58.com sees Q4 revenue up 12%-15% in RMB terms »

Based on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BILI

Bilibili

$16.39

-0.32 (-1.92%)

18:03
11/18/19
11/18
18:03
11/18/19
18:03
Hot Stocks
Bilibili reports average MAUs reached 127.9M in Q3 »

Average monthly active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

WUBA

58.com

$50.26

-1.35 (-2.62%)

18:03
11/18/19
11/18
18:03
11/18/19
18:03
Earnings
58.com reports Q3 adjusted EPS 96c, consensus 82c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BILI

Bilibili

$16.39

-0.32 (-1.92%)

18:01
11/18/19
11/18
18:01
11/18/19
18:01
Earnings
Bilibili reports Q3 adjusted EPS (15c), consensus (14c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

DDOG

Datadog

$40.36

-0.33 (-0.81%)

, AMZN

Amazon.com

$1,752.70

15.21 (0.88%)

17:56
11/18/19
11/18
17:56
11/18/19
17:56
Hot Stocks
Datadog announces support for AWS CloudFormation Registry and CLI »

Datadog (DDOG) announced…

DDOG

Datadog

$40.36

-0.33 (-0.81%)

AMZN

Amazon.com

$1,752.70

15.21 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

17:55
11/18/19
11/18
17:55
11/18/19
17:55
Conference/Events
Morgan Stanley analyst to hold an analyst/industry conference call »

Managing Director &…

GVA

Granite Construction

$26.50

-0.6 (-2.21%)

17:54
11/18/19
11/18
17:54
11/18/19
17:54
Hot Stocks
Granite Construction awarded $14M airfield improvement project in California »

Granite announced it was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZS

Zscaler

$44.46

-1.37 (-2.99%)

, MSFT

Microsoft

$150.35

0.4 (0.27%)

17:51
11/18/19
11/18
17:51
11/18/19
17:51
Initiation
Zscaler, Microsoft initiated at DA Davidson »

Zscaler initiated with a…

ZS

Zscaler

$44.46

-1.37 (-2.99%)

MSFT

Microsoft

$150.35

0.4 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

  • 04

    Dec

  • 09

    Dec

  • 16

    Dec

OKTA

Okta

$121.21

3.76 (3.20%)

17:51
11/18/19
11/18
17:51
11/18/19
17:51
Upgrade
Okta rating change at DA Davidson »

Okta pullback represents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 16

    Dec

PANW

Palo Alto Networks

$248.50

1.465 (0.59%)

17:48
11/18/19
11/18
17:48
11/18/19
17:48
Initiation
Palo Alto Networks initiated at DA Davidson »

Palo Alto Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Nov

  • 09

    Dec

CRWD

Crowdstrike

$57.06

-2.73 (-4.57%)

, AMZN

Amazon.com

$1,752.70

15.21 (0.88%)

17:47
11/18/19
11/18
17:47
11/18/19
17:47
Initiation
Crowdstrike, Amazon.com initiated at DA Davidson »

Crowdstrike valuation…

CRWD

Crowdstrike

$57.06

-2.73 (-4.57%)

AMZN

Amazon.com

$1,752.70

15.21 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 05

    Dec

  • 12

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.